RosVivo Therapeutics

Executive Summary

RosVivo Therapeutics is a private, preclinical-stage biotechnology company headquartered in San Diego, California, founded in 2018. The company specializes in developing novel microRNA (miRNA)-based therapeutics for metabolic diseases, with lead programs targeting diabetes, obesity, and related conditions. By focusing on the genetic and epigenetic regulation underlying these disorders, RosVivo aims to provide breakthrough therapies that address root causes rather than just symptoms. The company's platform leverages miRNA modulation to restore metabolic homeostasis, offering a potentially differentiated approach compared to conventional small molecules or biologics. As a private entity, RosVivo has limited public disclosures, but its pipeline is positioned to address large and growing markets with significant unmet medical needs.

Upcoming Catalysts (preview)

• Q3 2026Preclinical proof-of-concept data in diabetic mouse models60% success
• TBDSubmission of Investigational New Drug (IND) application for lead candidate30% success
• TBDStrategic partnership or licensing deal for metabolic pipeline40% success